2025-07-10 - Analysis Report
Okay, here's the report based on the data you provided, formatted for clarity and conciseness:

**Report: Transmedics Group Inc (TMDX) Analysis**

**Company Overview:** Transmedics Group Inc. is a medical technology company focused on developing and delivering innovative organ preservation systems for transplant therapy.

**1. Performance vs. S&P 500 (VOO)**

*   **Key Numbers:**
    *   TMDX Cumulative Return: 239.79%
    *   VOO Cumulative Return: 66.49%
    *   Absolute Divergence: 174.8
    *   Relative Divergence: 66.3 (Indicates TMDX's current divergence is in the 66.3rd percentile of its historical range relative to VOO)

*   **Analysis:** TMDX has significantly outperformed the S&P 500 (VOO).  The relative divergence suggests that while the outperformance is substantial, it is not at its extreme historically.

*   **Alpha/Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2019-2021  | -4.0%  | 63.4%  | -52.0%  | 0.0    | 0.7    |
| 2020-2022  | 140.0% | 68.3%  | 138.0%  | 0.1    | 2.1    |
| 2021-2023  | 95.0%  | 69.4%  | 77.0%   | 0.2    | 2.7    |
| 2022-2024  | 147.0% | 82.8%  | 121.0%  | 0.2    | 2.1    |
| 2023-2025  | 121.0% | 82.8%  | 74.0%   | 0.5    | 4.2    |

*   **Analysis:** The table shows that over various periods, TMDX has high CAGR (Compound Annual Growth Rate) but also significant MDD (Maximum Drawdown), indicating high volatility. Alpha is consistently high, suggesting outperformance relative to its benchmark. Beta is also generally high and increasing, indicating the stock is more volatile than the market. Market cap shows growth over time.

**2. Recent Price Action**

*   **Key Numbers:**
    *   Current Price: 125.63
    *   Last Market Data: Price 125.35, Previous Close 124.73, Change: 0.5
    *   5-Day Moving Average: 127.56
    *   20-Day Moving Average: 132.84
    *   60-Day Moving Average: 115.88

*   **Analysis:** The current price is below both the 5-day and 20-day moving averages, suggesting short-term downward momentum. The price is above the 60-day moving average, indicating a longer-term uptrend.  The minor change (0.5) from the previous close doesn't signal any dramatic short-term price event.

**3. Technical Indicators & Outlook**

*   **Key Numbers:**
    *   MRI (Market Risk Indicator): 0.3373 (Low Risk)
    *   RSI (Relative Strength Index): 33.43 (Oversold)
    *   PPO (Percentage Price Oscillator): -1.43
    *   Delta_Previous_Relative_Divergence (20-day): -2.1 (Negative Trend)
    *   Hybrid Signal: cash_69%_Sell 0.7% of holdings (4 shares - Caution - MRI:0.35) (Cash Ratio: 69% on 2025-06-16)
    *   Expected Return: 51.3% (Over S&P 500, long-term)

*   **Analysis:**
    *   The MRI indicates a low-risk environment.
    *   The RSI suggests the stock may be oversold and could potentially rebound.
    *   The negative PPO reinforces the downward momentum suggested by the moving averages.
    *   The decreasing relative divergence indicates a short-term downtrend.
    *   The Hybrid Signal recommends a slightly cautious approach, suggesting to reduce holdings and increase cash.
    *   The high Expected Return suggests strong long-term potential.

**4. Recent News & Events**

*   **Summary:** Recent news indicates that TMDX is experiencing volatility and is subject to analyst discussions regarding its performance, industry trends, and global economic factors. Investors are advised to monitor news and company announcements.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 예상 EPS |
|------------|-------|----------|
| 2025-05-08 | 0.7   | 0.29     |
| 2025-02-27 | 0.19  | 0.22     |
| 2024-10-28 | 0.12  | 0.29     |
| 2024-07-31 | 0.35  | 0.21     |
| 2024-04-30 | 0.35  | 0.03256  |

*   **Analysis:** TMDX has consistently exceeded EPS expectations in recent quarters, which is a positive sign. However, it's important to note that past performance is not indicative of future results.

**6. Financial Information**

*Revenue and Profitability:*

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|----------------|
| 2025-03-31 | $0.14B    | 61.47%         |
| 2024-12-31 | $0.12B    | 59.21%         |
| 2024-09-30 | $0.11B    | 55.94%         |
| 2024-06-30 | $0.11B    | 60.59%         |
| 2024-03-31 | $0.10B    | 61.91%         |

*Capital and Profitability:*

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-03-31 | $0.27B    | 9.64%    |
| 2024-12-31 | $0.23B    | 3.00%    |
| 2024-09-30 | $0.21B    | 2.01%    |
| 2024-06-30 | $0.19B    | 6.42%    |
| 2024-03-31 | $0.16B    | 7.65%    |

*   **Analysis:** Revenue shows a consistent upward trend. Profit margins are very high and relatively stable. Equity is increasing, and ROE (Return on Equity) is volatile, but the most recent data shows a significant increase, which is generally positive.

**7. Overall Summary**

TMDX demonstrates a compelling but complex picture. It has significantly outperformed the S&P 500 historically.  The company shows strong revenue growth, very high profit margins, and positive earnings surprises.  However, it also exhibits high volatility, as indicated by MDD and Beta.  Recent price action suggests short-term downward momentum, but long-term prospects remain positive, as reflected in the high expected return. Technical indicators like RSI suggest it *may* be oversold, while the hybrid signal is slightly cautious.

**Investment Recommendation:**

Given the strong fundamentals, high growth potential, and recent price weakness, TMDX *could* be a compelling long-term investment. However, investors should be aware of the high volatility and potential for significant drawdowns. A gradual accumulation strategy may be appropriate. Monitoring news and company announcements is crucial. The recommendation from the hybrid signal is to reduce holdings, so a contrarian might consider taking the opposite approach and adding slightly at this level.

*Disclaimer: This is a summary based on the provided data and does not constitute financial advice. Consult with a qualified financial advisor before making any investment decisions.*
